ストックスクリーナーアプリを入手
301.52
0.83%
2.48
アフターアワーズ：
301.52
Ligand Pharmaceuticals Inc (LGND) 最新ニュース
Barclays Initiates Outperform on Ligand Pharmaceuticals (LGND) w - GuruFocus
Ligand Pharma a new Outperform at Barclays on biopharma royalty aggregation - TradingView
Ligand Pharmaceuticals Incorporated (LGND) Stock Price, News, Quote & History - Yahoo! Finance Canada
LGND Initiated Coverage by Barclays -- Rating Set to Overweight - GuruFocus
Barclays Begins Coverage on Ligand Pharmaceuticals (NASDAQ:LGND) - MarketBeat
Barclays initiates Ligand Pharma stock with overweight rating By Investing.com - Investing.com South Africa
Barclays initiates Ligand Pharma stock with overweight rating - Investing.com
US53220KAJ7 Bond Profile: Coupon and Redemption - TradingView
Ligand Pharmaceuticals Director Martine Zimmermann Reports RSU Tax Withholding on 115 Shares - Kalkine Media
Form 4 Ligand Pharmaceuticals Incorporated For: 24 September By Investing.com - Investing.com Canada
Ligand, AvenCell ink financing deal worth up to $47M for CAR-T therapies - TradingView
LGND Reiterated by HC Wainwright & Co. -- Price Target Maintained at $358 - GuruFocus
LGND Looks 60.8% Overvalued on GF Value™ - GuruFocus
Oppenheimer reiterates Ligand Pharma stock rating on AvenCell deal By Investing.com - Investing.com Canada
LGND Looks 60.6% Overvalued on GF Value™ - GuruFocus
Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo! Finance Canada
Ligand Pharmaceuticals Invests Up to $47 Million in AvenCell - marketscreener.com
Up to $47 million could help advance AvenCell's treatments for two blood cancers. - Stock Titan
Ligand and AvenCell Therapeutics Enter Financing Agreement - GlobeNewswire
Ligand Pharmaceuticals Incorporated (LGND) stock price, news, quote and history - Yahoo Finance UK
Ligand Pharmaceuticals (LGND) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
McDermott Will & Schulte advises Ligand Pharmaceuticals in $23 million acquisition of royalty and milestone interest in Santen’s Ryjunea® - McDermott Will & Schulte
LGND Maintained by Citigroup -- Price Target Raised to $397 - GuruFocus
Sydnexis sells Ryjunea EMEA royalty rights to Ligand for $23 million upfront - The Pharma Letter
Ligand Acquires Royalty Rights in Santen’s Ryjunea from Sydnexis for $23 Million - VisionMonday.com
LGND Looks 56.0% Overvalued on GF Value™ - GuruFocus
Sydnexis Announces Royalty Agreement with Ligand for Ryjunea® - finance.yahoo.com
A production platform used in six approved biologics gets new funding. Primrose Bio will help expand its reach. - Stock Titan
Ligand Acquires Ryjunea Royalty Rights From Sydnexis for $23 Million - Minichart
Ligand Pharmaceuticals Acquires Ryjunea Royalty Interest for $23 Million - finance.yahoo.com
Ligand Acquires Ryjunea EMEA Royalty Rights for $23M Upfront - TradingView
About 1 in 3 European children and teens may be nearsighted by 2050. Ligand buys rights to a children's eye drop. - Stock Titan
LGNZZ 8-K FilingsLIGAND PHARMS BETA CVR SEC 8-K - Stock Titan
Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million - GlobeNewswire
Here’s How Much You Would Have Made Owning Ligand Pharmaceuticals Stock In The Last 5 Years - Benzinga
Ligand Pharmaceuticals: The Multiple Is The Whole Bet; Hold - Seeking Alpha
Ligand Pharmaceuticals seen as a strong midcap pharma despite recent 10% drop, with promising royalty assets. - Pluang
TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits
ETFs Investing in Ligand Pharmaceuticals Incorporated Stocks - TradingView
A Ligand (NASDAQ: LGND) director is planning a stock sale; the filing shows how big - Stock Titan
Ligand Pharmaceuticals CLO Reardon sells $1.43m in stock By Investing.com - Investing.com Australia
Ligand Pharmaceuticals (LGND) Rides Royalty Growth Hopes, Is The Stock Still Undervalued? - simplywall.st
Ligand Pharmaceuticals CLO Reardon sells $1.43m in stock - Investing.com
Ligand Pharmaceuticals Incorporated (LGND) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Ligand Pharmaceuticals (LGND): Massive XOMA Acquisition Doubles The Royalty Book - Yahoo Finance
Ligand (NASDAQ: LGND) insider to sell 15,000 shares after plan trades - Stock Titan
XOMA Royalty Reports $41.2M First-Half Net Loss on Trial Failures - Minichart
If You Invested $100 In Ligand Pharmaceuticals Stock 5 Years Ago, You Would Have This Much Today - Benzinga
A cash-heavy royalty arm at Ligand (NASDAQ: LGND) is loss-making - Stock Titan
Price to earnings forward of Ligand Pharmaceuticals Incorporated – OTC:LGNXZ - TradingView
Enterprise value to EBITDA forward of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView
Ligand Pharmaceuticals at Midwest IDEAS: royalty model gains scale By Investing.com - Investing.com Canada
Ligand to Participate in September Investor Conferences - marketscreener.com
Ligand (LGND) Snapshot: Ends Down by 2.13% at $280.18 for the Current Session; Price Setup: the Supplied Trading Band Runs From $266.17 to $294.19 at the CloseEarnings Breakout Stocks - vinanet.vn
Ligand (LGND) Chart: Retreats 0.38% to $286.29 in Latest Trading; Chart Watch: $271.98 and $300.60 Define the Nearby Reference Levels in the Available RecordMomentum Trade - vinanet.vn
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):